Ginkgo bioworks teams up with partners on arpa-h project to stabilize pharmaceutical supply chains - using amber waves of grain

Ginkgo bioworks and partners awarded $29 million contract by arpa-h to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems boston , april 10, 2025 /prnewswire/ -- ginkgo bioworks (nyse: dna), which is building the leading platform for cell programming and biosecurity, today announced a new contract with the advanced research projects agency for health (arpa-h), alongside partners tritica biosciences , us pharmacopeia (usp), on demand pharmaceuticals , and isolere bio by donaldson . this two-year program, wheat-based high efficiency enzyme and api technology (wheat), aims to establish a new manufacturing process for the distributed production of biologic and small molecule active pharmaceutical ingredients (apis) using wheat germ cell-free expression systems.
DNA Ratings Summary
DNA Quant Ranking